Onconetix appoints David White CEO, Sammy Dorf to board; Ramdeen resigns

Onconetix, Inc.

David White appointed CEO effective March 18, 2026; monthly base salary of $21,700.
Timothy Ramdeen resigned from board and committees on March 19, 2026; no disagreement.
Sammy Dorf appointed to board and audit committee effective March 19, 2026.
Compensation reductions: Fedasz reduced by $5,000/mo, Oakley reduced by $26,000/mo, effective March 18.
White's employment agreement includes one-year non-compete and confidentiality covenants.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David White

Chief Executive Officer

ONCO · Onconetix, Inc.

Effective: 2026-03-18
Filed: Mar 25, 2026 23:59 UTC

On March 18, 2026, the Board of Directors (the “ Board ”) of Onconetix, Inc, a Delaware corporation (the “ Company ”) appointed David White as Chief Executive Officer of the Company effective as of that date.

Departed

Timothy Ramdeen

Director

ONCO · Onconetix, Inc.

Effective: 2026-03-19
Filed: Mar 25, 2026 23:59 UTC

On March 19, 2026, Timothy Ramdeen notified the Chairman of the Board of his resignation from the Board, including from his service on the Audit Committee, Compensation Committee and the Nominating and Corporate Governance Committee of the Board, effective immediately.

Source: SEC EDGAR

accession 0001213900-26-034054

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.